SecBot SecBot
SECBOTREPLAY Home › Report › APGE

APGE · Apogee filed supplementary proxy materials (DEFA14A) on August 3, 2026,…

Apogee Therapeutics, Inc. · DEFA14A filed Aug 3, 2026 at 17:10 ET

At the news

BULLISHIMPACT 5/10

DEFA14A filed Aug 3, 2026 at 17:10 ET

Apogee filed supplementary proxy materials (DEFA14A) on August 3, 2026, updating stockholders ahead of the August 11 special meeting to vote on the $135.11/share all-cash acquisition by AbbVie. The supplement addresses a pending stockholder lawsuit (Smith Complaint) alleging inadequate disclosures, adds voluntary disclosures on financial projections and fairness opinions, and confirms German antitrust clearance (FCO) was obtained on July 27, 2026, with an Australian ACCC filing underway. The board reiterates its unanimous recommendation for approval, and non-voting stock holders have already consented. The deal remains on track with the record-date share count updated to 62,140,183 voting shares outstanding; a majority of 31,070,092 votes is needed for approval.

  • Merger consideration is $135.11 per share in cash, with Apogee stockholders to receive that amount upon closing
  • Special meeting of stockholders to vote on the merger is scheduled for August 11, 2026 at 9:00 a.m. Eastern time
  • As of the record date (July 10, 2026), there were 62,140,183 shares of voting common stock outstanding; directors and officers beneficially owned 1,412,999 shares (2.27%)
  • Majority approval requires 31,070,092 affirmative votes; non-voting common stock holders have already delivered written consent to the merger

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access